Acute Ischemic Stroke – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Acute Ischemic Stroke – Pipeline Review, H2 2016’, provides an overview of the Acute Ischemic Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke

The report reviews pipeline therapeutics for Acute Ischemic Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acute Ischemic Stroke therapeutics and enlists all their major and minor projects

The report assesses Acute Ischemic Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acute Ischemic Stroke

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

AstraZeneca Plc

Biogen Inc

D-Pharm Ltd.

Daiichi Sankyo Company, Limited

DiaMedica Inc.

Digna Biotech, S.L.

Glucox Biotech AB

Jeil Pharmaceutical Co., Ltd.

Lumosa Therapeutics Co., Ltd.

Mitsubishi Tanabe Pharma Corporation

Pharmicell Co., Ltd.

PhytoHealth Corporation

Remedy Pharmaceuticals, Inc.

Saneron CCEL Therapeutics, Inc.

Simcere Pharmaceutical Group

Stemedica Cell Technologies, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Acute Ischemic Stroke Overview 9

Therapeutics Development 10

Pipeline Products for Acute Ischemic Stroke - Overview 10

Acute Ischemic Stroke - Therapeutics under Development by Companies 11

Acute Ischemic Stroke - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Acute Ischemic Stroke - Products under Development by Companies 16

Acute Ischemic Stroke - Companies Involved in Therapeutics Development 18

AB Science SA 18

AstraZeneca Plc 19

Biogen Inc 20

D-Pharm Ltd. 21

Daiichi Sankyo Company, Limited 22

DiaMedica Inc. 23

Digna Biotech, S.L. 24

Glucox Biotech AB 25

Jeil Pharmaceutical Co., Ltd. 26

Lumosa Therapeutics Co., Ltd. 27

Mitsubishi Tanabe Pharma Corporation 28

Pharmicell Co., Ltd. 29

PhytoHealth Corporation 30

Remedy Pharmaceuticals, Inc. 31

Saneron CCEL Therapeutics, Inc. 32

Simcere Pharmaceutical Group 33

Stemedica Cell Technologies, Inc. 34

Acute Ischemic Stroke - Therapeutics Assessment 35

Assessment by Monotherapy Products 35

Assessment by Target 36

Assessment by Mechanism of Action 39

Assessment by Route of Administration 42

Assessment by Molecule Type 44

Drug Profiles 46

3K3A-APC - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

AB-022 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

ApTLR-4FT - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Cellgram-IS - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

DB-017 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

DM-199 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

DS-1040 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

glyburide - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

HBI-002 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

HBN-1 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

JPI-289 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

LT-3001 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

masitinib - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

MP-124 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

natalizumab - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Neu-2000 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

PHN-014 - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Rejuveinix - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

SIM-071201 - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

Stem Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

THR-18 - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

ticagrelor - Drug Profile 103

Product Description 103

Mechanism Of Action 103

R&D Progress 103

TMS-007 - Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

Acute Ischemic Stroke - Dormant Projects 112

Acute Ischemic Stroke - Discontinued Products 115

Acute Ischemic Stroke - Product Development Milestones 117

Featured News & Press Releases 117

Sep 12, 2016: DiaMedica Announces Regulatory Clearance to Initiate Bridging Clinical Trial for DM199 117

Jun 14, 2016: DiaMedica Announces U.S. Composition of Matter Patent for DM199 117

Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia 117

Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial 118

Nov 04, 2015: DiaMedica Provides Corporate Update 118

Oct 09, 2015: Remedy Pharmaceuticals’ Drug CIRARAâ„¢ Cut Death Rates from Severe Stroke by More Than Half 120

Sep 29, 2015: Remedy Pharmaceuticals Announces Phase 2 Severe Stroke Study Results to Be Presented at Neurocritical Care Annual Meeting 123

Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference 123

Dec 18, 2014: D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA 123

Nov 04, 2014: D-Pharm Reports First Results From its Phase 2 Clinical Study of THR-18 In Acute Stroke Patients Treated with tPA 124

Aug 19, 2014: US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA 125

Jun 02, 2014: D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA 125

Apr 22, 2014: ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures 126

Mar 04, 2014: D-Pharm reports the successful interim analysis of its Phase 2 clinical study of THR-18 in acute stroke patients 127

Jan 21, 2014: D-Pharm completes recruitment of patients into the first dosage tier of its Phase 2 study with THR-18 in acute stroke patients treated with tPA 127

Appendix 129

Methodology 129

Coverage 129

Secondary Research 129

Primary Research 129

Expert Panel Validation 129

Contact Us 129

Disclaimer 130

List of Tables

List of Tables

Number of Products under Development for Acute Ischemic Stroke, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Development by Companies, H2 2016 (Contd..1) 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Acute Ischemic Stroke – Pipeline by AB Science SA, H2 2016 18

Acute Ischemic Stroke – Pipeline by AstraZeneca Plc, H2 2016 19

Acute Ischemic Stroke – Pipeline by Biogen Inc, H2 2016 20

Acute Ischemic Stroke – Pipeline by D-Pharm Ltd., H2 2016 21

Acute Ischemic Stroke – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 22

Acute Ischemic Stroke – Pipeline by DiaMedica Inc., H2 2016 23

Acute Ischemic Stroke – Pipeline by Digna Biotech, S.L., H2 2016 24

Acute Ischemic Stroke – Pipeline by Glucox Biotech AB, H2 2016 25

Acute Ischemic Stroke – Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 26

Acute Ischemic Stroke – Pipeline by Lumosa Therapeutics Co., Ltd., H2 2016 27

Acute Ischemic Stroke – Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 28

Acute Ischemic Stroke – Pipeline by Pharmicell Co., Ltd., H2 2016 29

Acute Ischemic Stroke – Pipeline by PhytoHealth Corporation, H2 2016 30

Acute Ischemic Stroke – Pipeline by Remedy Pharmaceuticals, Inc., H2 2016 31

Acute Ischemic Stroke – Pipeline by Saneron CCEL Therapeutics, Inc., H2 2016 32

Acute Ischemic Stroke – Pipeline by Simcere Pharmaceutical Group, H2 2016 33

Acute Ischemic Stroke – Pipeline by Stemedica Cell Technologies, Inc., H2 2016 34

Assessment by Monotherapy Products, H2 2016 35

Number of Products by Stage and Target, H2 2016 37

Number of Products by Stage and Mechanism of Action, H2 2016 40

Number of Products by Stage and Route of Administration, H2 2016 43

Number of Products by Stage and Molecule Type, H2 2016 45

Acute Ischemic Stroke – Dormant Projects, H2 2016 112

Acute Ischemic Stroke – Dormant Projects (Contd..1), H2 2016 113

Acute Ischemic Stroke – Dormant Projects (Contd..2), H2 2016 114

Acute Ischemic Stroke – Discontinued Products, H2 2016 115

Acute Ischemic Stroke – Discontinued Products (Contd..1), H2 2016 116

List of Figures

List of Figures

Number of Products under Development for Acute Ischemic Stroke, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 35

Number of Products by Top 10 Targets, H2 2016 36

Number of Products by Stage and Top 10 Targets, H2 2016 36

Number of Products by Top 10 Mechanism of Actions, H2 2016 39

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 39

Number of Products by Routes of Administration, H2 2016 42

Number of Products by Stage and Routes of Administration, H2 2016 42

Number of Products by Molecule Types, H2 2016 44

Number of Products by Stage and Molecule Types, H2 2016 44

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports